Poulsom R, Hanby A M, Lalani E N, Hauser F, Hoffmann W, Stamp G W
ICRF Histopathology Unit, London, U.K.
J Pathol. 1997 Sep;183(1):30-8. doi: 10.1002/(SICI)1096-9896(199709)183:1<30::AID-PATH1085>3.0.CO;2-K.
pS2-TFF 1 is expressed in breast cancers and has been investigated as a potential prognostic factor reflecting oestrogen dependence. The relationship to the expression of other trefoil peptides, human spasmolytic polypeptide (hSP-TFF 2) and intestinal trefoil factor (hITF/hPI.B-TFF 3) is documented here. Fifty-seven breast specimens were selected from surgical pathology archives and included five normal breasts (two lactating), seven benign proliferative lesions, 11 ductal carcinomas in situ (DCIS), three lobular carcinomas in situ (LCIS), 24 invasive ductal carcinomas (IDC), and seven invasive lobular carcinomas (ILC). The comparative distribution of trefoil mRNAs was assessed by in situ hybridization using 35S-labelled riboprobes and immunohistochemical staining for pS2-TFF 1 and hSP-TFF 2. pS2-TFF 1 and hITF/hPI.B-TFF 3 mRNA were focally present at low signal intensity in normal and benign breast. Both pS2-TFF 1 and hITF/hPI.B-TFF 3 were expressed in all DCIS, LCIS and ILC, and 21/24 IDC. Overall, expression patterns of pS2-TFF 1 and hITF/hPI.B-TFF 3 coincided, but hITF/hPI.B-TFF 3 mRNA was usually found in a greater proportion of cells. Expression of hSP-TFF 2 peptide or mRNA was not detected in any of these cases. MCF 7 breast carcinoma cells also expressed hITF/hPI.B-TFF 3 and pS2-TFF 1 mRNAs but not hSP-TFF 2. hITF/hPI.B-TFF 3 co-expression with pS2-TFF 1 may act as a prognostic factor, but also raises questions about the regulatory pathway for pS2-TFF 1 hITF/hPI.B-TFF 3. Trefoil factors have effects on cell motility and spreading in vitro, and co-expression of hITF/hPI.B-TFF 3 with pS2-TFF 1 could be functionally significant if they form a heterodimer or compete for receptor binding. Absence of hSP-TFF 2 expression may be of equal relevance to tumour cell biology.
pS2-TFF 1在乳腺癌中表达,并已作为反映雌激素依赖性的潜在预后因素进行了研究。本文记录了其与其他三叶肽,即人解痉多肽(hSP-TFF 2)和肠三叶因子(hITF/hPI.B-TFF 3)表达的关系。从外科病理档案中选取了57份乳腺标本,包括5份正常乳腺(2份哺乳期)、7份良性增生性病变、11份导管原位癌(DCIS)、3份小叶原位癌(LCIS)、24份浸润性导管癌(IDC)和7份浸润性小叶癌(ILC)。使用35S标记的核糖探针通过原位杂交以及对pS2-TFF 1和hSP-TFF 2进行免疫组织化学染色来评估三叶因子mRNA的相对分布。pS2-TFF 1和hITF/hPI.B-TFF 3 mRNA在正常和良性乳腺中以低信号强度局灶性存在。pS2-TFF 1和hITF/hPI.B-TFF 3在所有DCIS、LCIS和ILC以及21/24的IDC中均有表达。总体而言,pS2-TFF 1和hITF/hPI.B-TFF 3的表达模式一致,但hITF/hPI.B-TFF 3 mRNA通常在更大比例的细胞中被发现。在这些病例中均未检测到hSP-TFF 2肽或mRNA的表达。MCF 7乳腺癌细胞也表达hITF/hPI.B-TFF 3和pS2-TFF 1 mRNA,但不表达hSP-TFF 2。hITF/hPI.B-TFF 3与pS2-TFF 1的共表达可能作为一种预后因素,但也引发了关于pS2-TFF 1 hITF/hPI.B-TFF 3调控途径的问题。三叶因子在体外对细胞运动和扩散有影响,如果hITF/hPI.B-TFF 3与pS2-TFF 1形成异二聚体或竞争受体结合,它们的共表达可能在功能上具有重要意义。hSP-TFF 2表达的缺失可能与肿瘤细胞生物学同样相关。